Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-06-01 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
独立董事制度（2018年6月）
Governance Information Classification · 95% confidence The document is titled '深圳华大基因股份有限公司 独立董事制度' which translates to 'Shenzhen BGI Genomics Co., Ltd. Independent Director System'. It details the rules, qualifications, nomination, election, duties, and working conditions of independent directors at the company. The content is focused on governance structure, board composition, director responsibilities, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document outlining internal rules and practices for independent directors. Therefore, it fits best under the category of Governance Information (CGR). The document length (8157 characters) and detailed content confirm it is a full governance policy document, not a brief announcement or regulatory filing.
2018-06-01 Chinese
关于召开2018年第二次临时股东大会的通知公告
AGM Information Classification · 95% confidence The document is a detailed notice and announcement regarding the convening of the 2018 second extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, agenda items, voting procedures, and candidate elections for board and supervisory positions. The content focuses on governance matters such as board member elections and amendments to the company's articles of association. There is no financial data or earnings information, nor is it a transcript or presentation. It is not a report publication announcement but a formal meeting notice and related materials. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2018-06-01 Chinese
独立董事提名人声明（三）
Board/Management Information Classification · 100% confidence The document is a formal statement from the board of Shenzhen BGI Genomics Co., Ltd. nominating an independent director candidate. It contains detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. There is no financial data, no discussion of financial results, no mention of annual or interim reports, earnings, or capital changes. The content is focused on board/management information specifically related to the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not a mere announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2018-06-01 Chinese
独立董事提名人声明（二）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board of Shenzhen BGI Genomics Co., Ltd. nominating an independent director candidate, Xu Aimin. It includes detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. The content focuses on board nomination and governance compliance rather than financial results, audit, or shareholder voting outcomes. There is no indication of financial data, earnings, or report publication. The document is clearly related to board/management information, specifically the nomination of a board member.
2018-06-01 Chinese
独立董事提名人声明（一）
Board/Management Information Classification · 100% confidence The document is a formal public statement from the board of Shenzhen BGI Genomics Co., Ltd. nominating an individual as an independent director candidate. It includes detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. The content focuses on board nomination and compliance with director eligibility rules rather than financial results, audit opinions, or shareholder voting outcomes. There is no indication of financial data, earnings, or meeting results. This type of document is best classified under Board/Management Information (MANG) as it pertains to changes or announcements related to the company's board of directors.
2018-06-01 Chinese
独立董事关于第一届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding matters discussed at the 21st meeting of the first board of directors, including adjustments to the board size and the nomination of candidates for the second board. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on governance matters, board member qualifications, and election procedures. There is no financial data, earnings information, or audit content. The document is not a report or announcement of financial results but a governance-related statement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2018-06-01 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.